Alec Stranahan
BofA Securities, Research Division

Hey, everyone. Thanks for joining the session with Erasca. My name is Alec Stranahan. I cover SMID Biotech at Bank of America. And I'm covering analyst for Erasca. And I have the pleasure of introducing and being joined by Jonathan Lim, Chairman and CEO; and David Chacko, Chief Financial Officer and CEO of Erasca. Thanks for being here, guys.

Jonathan Lim
Co-Founder, Chairman & CEO

Thank you, Alec. Great to be here.

Alec Stranahan
BofA Securities, Research Division

Yes. Looking forward to the conversation.

Alec Stranahan
BofA Securities, Research Division

Maybe just to start, just to put the updates in context, and we'll definitely dig into those. But just at a high level, we've seen an evolution in RAS targeted therapies over the past 10 years, right? It started with unlocking the binding site for KRAS G12C. And now we've advanced to G12D and pan-RAS. You recently presented your Phase I update for double -- for ERAS-0015, which is your next-generation pan-RAS inhibitor. Response rates that were potentially best-in-class. So maybe just to start off, I guess how are you viewing the competitive setup for your RAS programs broadly? And what are sort of the upcoming readouts that get you most excited?

Jonathan Lim
Co-Founder, Chairman & CEO

Yes. So you talked about the evolution of the space. I mean I think we're at a really exciting point in history in targeted therapy where you can go after a previously intractable target like RAS and actually have a pan-RAS compound make a